Palatin Tech To Cut Work Force In Half, Do Reverse Stock Split – Wall Street Journal

Palatin Tech To Cut Work Force In Half, Do Reverse Stock Split
Wall Street Journal
Palatin has been developing bremelanotide for male and female sexual dysfunction and PL-3994 for acute severe asthma. The company plans to submit plans for
Palatin Announces Strategic Realignment of OperationsPR Newswire (press release)
Palatin Reducing Workforce By 50%; To Effect 1-for-10 Reverse Stock Split RTT News

all 17 news articles »

View full post on asthma – Google News

UK’s NICE Rejects Novartis’ Xolair Again In Kids Aged 6 To 11 – Wall Street Journal


MSN News UK

UK's NICE Rejects Novartis' Xolair Again In Kids Aged 6 To 11
Wall Street Journal
or NICE, Thursday reiterated its earlier decision not to recommend Novartis AG's (NVS) asthma drug Xolair for children aged 6 to 11 years with severe,
Asthma rises as children return to schoolTelegraph.co.uk
September marks child asthma peakThe Press Association
Children with asthma 'at greater risk during September'MadeForMums
Visit Bulgaria –TopNews United Kingdom (blog) –Candis
all 24 news articles »

View full post on asthma – Google News

CORRECT: Vectura Licenses Patents To GlaxoSmithKline – Wall Street Journal


Stockopedia

CORRECT: Vectura Licenses Patents To GlaxoSmithKline
Wall Street Journal
VX) generics unit Sandoz handed back the US rights to VR315, a generic version of an asthma drug, to Vectura. Analysts said it signaled Sandoz wasn't sure
INTERVIEW: Vectura Patents For GSK's 573719 And 642444Wall Street Journal
Vectura and GlaxoSmithKline sign agreement over asthma patentsStockopedia
Vectura boosted by deal with GSK worth over $30 million upfront plus royalties The Pharma Letter (subscription)

all 23 news articles »

View full post on asthma – Google News